Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Formoterol is an inhaled long-acting beta2-adrenergic receptor agonist used as a bronchodilator in the management of asthma and COPD. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers.
- Mechanism
- Curator reviewed · 6 references
Formoterol is a relatively selective long-acting agonist of beta2-adrenergic receptors, although it does carry some degree of activity at beta1 and beta3 receptors. Beta2 receptors are found predominantly in bronchial smooth muscle (with a relatively minor amount found in cardiac tissue) whereas beta1 receptors are the predominant adrenergic receptors found in the heart - for this reason, selectivity for beta2 receptors is desirable in the treatment of pulmonary diseases such as COPD and asthma. Formoterol has demonstrated an approximately 200-fold greater activity at beta2 receptors over beta1 receptors.
On a molecular level, activation of beta receptors by agonists like formoterol stimulates intracellular adenylyl cyclase, an enzyme responsible for the conversion of ATP to cyclic AMP (cAMP). The increased levels of cAMP in bronchial smooth muscle tissue result in relaxation of these muscles and subsequent dilation of the airways, as well as inhibition of the release of hypersensitivity mediators (e.g. histamine, leukotrienes) from culprit cells, especially mast cells.
- Primary indication
- Formoterol is indicated in various formulations for the treatment of asthma and COPD.Curator reviewed · 11 structured indications
- Formula / weight
- C19H24N2O4 · 344.4049 g/mol (avg)
- First approval
- Canada, 1997 · United States, 2001 · European Union, 2016
Resolves to
BPZSYCZIITTYBL-UHFFFAOYSA-NSMILESCOC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Formoterol, and which of those have an active Phase 3 trial?